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Growth hormone (GH) and β agonists increase muscle mass, but the mechanisms for this response are unclear and the magnitude
of response is thought to vary with age of animal. To investigate the mechanisms driving the muscle response to these agents,
we examined the effects of short-term (6 day) administration of GH or cimaterol (a β2-adrenergic agonist, BA) on skeletal muscle
phenotype in both young (day 60) and mature (day 120) lambs. Expression of myosin heavy chain (MyHC) isoforms were measured
in Longissimus dorsi (LD), Semitendinosus (ST) and Supraspinatus (SS) muscles as markers of ﬁbre type and metabolic enzyme
activities were measured in LD. To investigate potential mechanisms regulating the changes in ﬁbre type/metabolism, expression
or activity of a number of signalling molecules were examined in LD. There were no effects of GH administration on MyHC isoform
expression at either the mRNA or protein level in any of the muscles. However, BA treatment induced a proportional change in
MyHC mRNA expression at both ages, with the %MyHCI and/or IIA mRNA being signiﬁcantly decreased in all three muscles and
%MyHCIIX/IIB mRNA signiﬁcantly increased in the LD and ST. BA treatment induced de novo expression of MyHCIIB mRNA in LD,
the fastest isoform not normally expressed in sheep LD, as well as increasing expression in the other two muscles. In the LD, the
increased expression of the fastest MyHC isoforms (IIX and IIB) was associated with a decrease in isocitrate dehydrogenase
activity, but no change in lactate dehydrogenase activity, indicating a reduced capacity for oxidative metabolism. In both young
and mature lambs, changes in expression of metabolic regulatory factors were observed that might induce these changes in muscle
metabolism/ﬁbre type. In particular, BA treatment decreased PPAR-γ coactivator-1β mRNA and increased receptor-interacting
protein 140 mRNA. The results suggest that the two agents work via different mechanisms or over different timescales, with only
BA inducing changes in muscle mass and transitions to a faster, less oxidative ﬁbre type after a 6-day treatment.
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Implications
This study provides mechanistic information on the anabolic
responses to growth hormone and β-adrenergic agonist in
sheep muscle. It therefore has implications for the use of
these agents in farm animals, which is licensed in some parts
of the world (e.g. United States, Australia) but not others
(e.g. EU). Regarding cross-species comparisons, there are
clear differences in responses between sheep and rodents,
with sheep appearing to respond in a manner more similar
to humans than rats. Indeed, the ﬁbre type composition
of sheep muscle is more similar to humans than rats,
suggesting that sheep may be a better model organism for
conducting skeletal muscle studies.
Introduction
Administration of growth hormone (GH) or β-adrenergic
agonist (BA) results in the repartitioning of nutrients,
increasing skeletal muscle mass and decreasing fat mass
(Buttery and Dawson, 1990). The effectiveness of these
agents is thought to be reduced in young, rapidly growing
animals compared with those approaching mature BW (Bell
et al., 1998). In addition, the increase in skeletal muscle mass
may be dependent upon muscle ﬁbre type composition or
involve ﬁbre type transitions (Lefaucheur and Gerrard, 2000).
In recent years, measurement of myosin heavy chain (MyHC)
isoforms has been used to indicate the ﬁbre type composition† Email: john.brameld@nottingham.ac.uk
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of skeletal muscles (Sazili et al., 2005). In sheep and cattle,
the predominant MyHC isoforms expressed in adult animals
are types I, IIA and IIX, with the ‘fastest, most glycolytic’
isoform, MyHCIIB, being rarely detected in these species
(Hemmings et al., 2009; Picard and Cassar-Malek, 2009).
The factors involved in regulating ﬁbre type transitions are
poorly understood, particularly those relating to fast glyco-
lytic ﬁbre types. Rodent studies have identiﬁed a number of
potential regulatory signalling molecules, including the
myogenic regulatory factors (MRFs; Hughes et al., 1993) and
the signalling enzymes, calcineurin (CaN) and calmodulin
kinase II (CaMKII; Chin, 2005; Bassel-Duby and Olson, 2006).
The Six1/Eya1 protein complex has been shown to be
important in the regulation of the fast glycolytic ﬁbre type in
rodents (Grifone et al., 2004), but their role in other species
is not known. In addition, the peroxisome proliferator-
activated receptor (PPAR) transcription factors, along with
the PPAR-γ coactivator-1 (PGC-1) family of transcriptional
coactivators and the transcriptional co-repressor, receptor-
interacting protein 140 (RIP140), are all known to inﬂuence
muscle metabolic gene expression in rodents (Lin, 2009), but
again their role in other species is not known.
The objective of the current study was therefore to
compare the effects of short-term (6 day) treatment with GH
or BA on enzyme activities and expression of genes asso-
ciated with skeletal muscle metabolism and ﬁbre type in
young (rapidly growing) and mature (fattening) lambs.
BA had previously been shown to alter MyHC isoform
expression after 1 week of treatment in pigs (Gunawan et al.,
2007) and therefore this short-term (6 day) treatment
was chosen in order to investigate the initial (inductive)
response to these agents and potential regulatory mechan-
isms involved.
Material and methods
Sheep studies were approved by the University of Nottingham
Local Ethical Review Committee and were carried out in
accordance with the UK Home Ofﬁce guidelines (Animals
(Scientiﬁc Procedures) Act, 1986).
Sample collection and preparation
Male (Mule× Charolais) twin lambs were group housed with
their mothers until 53 ± 4 days of age, when they were
weaned and pairs were split into day 60 (D60) and day 120
(D120) groups. These ages were chosen based on a previous
(unpublished) study at the University of Nottingham, show-
ing that D60 was within the rapid growth phase and D120
represented mature lambs with reduced growth rates and
increased backfat deposition. Creep feed (48.48% barley,
27% soya, 15% nutritionally improved straw, 5% molassed
feed meal, 2.5% vitamins and minerals, 1% limestone, 0.5%
salt, 0.5% vegetable oil and 0.02% Minsal g109 E50) was
introduced ∼28 days before weaning and lambs were given
free access from weaning onwards. Lambs were individually
penned with ad-libitum access to creep feed for 7 days before
the commencement of treatments. The D60 and D120 groups
were split into three treatment groups, ensuring that the
mean initial BWs for each group were not signiﬁcantly
different. The control group (CO, n = 11) were fed the creep
diet ad libitum; the GH group (n = 10) were fed the same
diet ad libitum and administered a prolonged release bovine
GH formulation (POSILAC, Monsanto, St Louis, Missouri,
USA) on the 1st day of treatment by a single subcutaneous
injection ∼5 cm from the nape of the neck, at a dose of
3.75 mg/kg BW, as described by McLaughlin et al. (1994).
The BA group (n = 10) were fed the same creep diet
ad libitum, but containing the β2-adrenergic agonist,
cimaterol, at 10 ppm (10 mg/kg). The treatments were for
6 days, starting at 60 ± 4 or 120 ± 4 days of age. This
short-treatment period was chosen in order to investigate
the initial (inductive) response to these agents, particularly
in terms of intracellular signalling. At slaughter, blood
was collected and plasma prepared, while samples of the
Longissimus dorsi (LD, from the thoracic region at the
10th rib), Supraspinatus (SS) and Semitendinosus (ST) muscles
from the left side of the carcass, were snap frozen in liquid
nitrogen and stored at −80°C; these were subsequently
crushed and mixed before further analyses. LD and ST
muscles were chosen for their commercial importance and as
representative ‘fast’ muscles, whereas SS was selected as a
‘slower’ muscle type (Hemmings et al., 2009). The whole LD,
ST, SS, Vastus lateralis (Vlat) and Vastus intermedius (Vint)
muscles were dissected from the right side of the carcass and
weighed along with the liver, all within 1 h of slaughter.
Plasma IGF-I and glycerol concentrations and LD skeletal
muscle glycogen content
Plasma IGF-I concentrations were determined using an
enzyme-linked immunosorbent assay kit (Diagnostic Systems
Laboratories, Oxford, UK) and plasma glycerol concentra-
tions were measured using the Serum Triglyceride determi-
nation kit (Sigma Aldrich, Poole, UK), both procedures were
carried out according to the manufacturers’ instructions.
Acid-soluble muscle glycogen was determined using a pro-
tocol adapted from Dreiling et al. (1987). Brieﬂy, 1 g of
muscle was homogenised in 4 ml of 8% (vol/vol) perchloric
acid (PCA), then 1 ml was removed and centrifuged at
14 000× g at 4°C for 10 min. To neutralise the supernatant,
133 µl was mixed with 150 µl of saturated sodium bicarbo-
nate (5 M) solution and 167 µl of 200 mM sodium acetate
buffer, pH 4.8. A range of glycogen standards were prepared
in neutralised PCA containing 0 to 300 µg of bovine liver
glycogen (Sigma Aldrich) in a 200 µl volume. Amyloglucosi-
dase (5 µl of 80 U/ml, Sigma Aldrich) was added to 200 µl
of each standard or neutralised sample supernatant and
incubated at 37°C for 30 min to release the glucose from the
glycogen. Samples were heated at 100°C for 5 min to stop
the reaction and then centrifuged at 14 000× g for 10 min
at room temperature. Glucose concentrations were deter-
mined using Enzymatic Glucose Reagent (Thermo Electron
Corporation, Fife, UK), by measuring the absorbance at
550 nm on a 680 XR 96-well microplate reader (Bio-Rad,
Hemel Hempstead, UK).
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Skeletal muscle total RNA extraction and cDNA synthesis
Total RNA was extracted from LD, SS and ST muscle samples
using TRIZOL (Invitrogen, Paisley, UK), according to the
manufacturer’s instructions, and then treated with DNase
(Promega, Southampton, UK). Following DNase treatment,
RNA was quantiﬁed using the Nanodrop spectrophotometer
ND-1000 (Thermo Scientiﬁc, Wilmington, DE, USA) and RNA
integrity was checked by running samples on a 1% agarose
gel and visualising the 28S and 18S ribosomal RNA bands.
First strand complementary DNA (cDNA) was synthesised
from 1 µg of total RNA using random hexamer primers
and Moloney murine leukemia virus reverse transcriptase
(Promega) in a ﬁnal volume of 25 μl (Hemmings et al., 2009).
MyHC isoform expression
The relative expression of the adult MyHC isoforms (MyHCI,
IIA, IIX and IIB) were determined at both the mRNA and
protein level, as described previously (Hemmings et al.,
2009). Brieﬂy, SDS–PAGE separation of MyHC isoforms
was carried out to determine percentage MyHC protein
expression, comparing samples to a bovine positive control
(Longissimus thoracis) sample (kindly provided by Dr Brigitte
Picard, INRA, France) previously shown to express all four
adult MyHC isoforms (Picard and Cassar-Malek, 2009).
Quantitative real-time PCR was carried out on muscle cDNA
to determine percentage MyHC mRNA expression, using
ovine speciﬁc primers and probes for MyHCI, IIA and IIX
(Supplementary Table S1). The relative percentage of each
isoform was calculated as described previously (Hemmings
et al., 2009). Primers and probes designed to the available
sequence for the ovine MyHCIIX isoform would be expected to
generate amplicons from any MyHCIIB transcripts present as
well, as this region is identical in the porcine sequences for
MyHCIIX and IIB, therefore expression is stated as MyHCIIX/IIB.
The mRNA expression of the MyHCIIB isoform was analysed
by semi-quantitative RT-PCR using published primers pre-
viously described as detecting only ovine MyHCIIB (Vuocolo
et al., 2007). MyHCIIB expression was compared with the
semi-quantitative RT-PCR analysis of MyHCIIX+ IIB com-
bined (using the primers in Supplementary Table S1).
Metabolic enzyme activities
Isocitrate dehydrogenase (ICDH) and lactate dehydrogenase
(LDH) activities were determined in LD homogenates using the
methods described by Brandstetter et al. (1998) as an indica-
tion of oxidative and glycolytic metabolism, respectively.
CaN and calmodulin kinase activities
Protein content was determined in LD homogenates using
the Bradford assay (Bradford, 1976) and samples adjusted to
constant protein before assay. CaN activity was determined
in skeletal muscle homogenates using the BIOMOL CaN
cellular assay kit plus (Enzo Life Sciences Ltd, Exeter, UK).
CaMKII activity was determined using the SignaTECT calcium/
calmodulin-dependent protein kinase (CaMKII) Assay kit
(Promega).
Real-time PCR analysis of signalling molecule gene
expression
Ovine speciﬁc primers and probes were designed using
Primer Express software (Applied Biosystems, Warrington,
UK) and are shown in Supplementary Table S1. LD cDNA was
diluted 1 in 4 and a pool of samples generated and serially
diluted to generate a standard curve. Each sample cDNA was
further diluted 1 in 8 and 5 μl was used for real-time PCR
reactions (in triplicate), using 384 well plates and 1X Light-
cycler 480 probes master PCR mastermix (Roche, Burgess
Hill, UK) in 15 μl ﬁnal reaction volume (containing 0.3 μM of
each primer and 0.2 μM of probe). Reactions were run on the
Lightcycler 480 PCR machine (Roche) with the following
conditions: 95°C for 10 min and then 45 cycles of 95°C for
10 s, 60°C for 50 s and 72°C for 1 s, during which ﬂuore-
scence was measured. Crossing point (Cp) values were
determined using the second derivative maximum method
and quantiﬁed relative to the standard curve (Brown et al.,
2012). Supplementary Table S1 includes the primers used for
PCR. After being unable to ﬁnd a suitable housekeeping
gene for normalising the data, it was decided to express the
real-time data relative to the equivalent quantity of RNA in
the reaction, given that the total RNA concentrations had
been normalised before cDNA synthesis.
Statistical analysis
Data are presented as means or as a percentage value. All
data had a normal distribution. Data for each age group was
analysed separately by one-way ANOVA (Genstat release
11.1. (Lawes Agricultural Trust, Hertfordshire, UK)), blocking
for gel where appropriate. s.e.d. values are included for the
ANOVA. When signiﬁcant differences were observed (with
ANOVA), a post hoc Dunnett’s test was then used to com-
pare each treatment group to the control. If not signiﬁcant
(i.e. P> 0.05), the P-values shown relate to the ANOVA, but
in the text signiﬁcant differences are indicated using P-values
for the Dunnett’s test. Tables include the P-values for the
ANOVA, with * used to indicate signiﬁcant differences for
the Dunnett’s test.
Results
Lamb responsiveness to BA and GH treatments
The effects of a 6-day treatment with BA or GH on lamb
carcass characteristics are shown in Table 1. Neither treat-
ment signiﬁcantly altered BWs (P> 0.05) and there were
no signiﬁcant differences in any muscle weights at D60 or
in LD and VInt muscle weights at D120 (P> 0.05). However,
BA treatment resulted in signiﬁcant increases in SS and
ST muscle weights at D120 (P< 0.05), with VLat weights
also tending to be higher in the BA treated older lambs
(P = 0.058). As expected, GH signiﬁcantly increased liver
weights (P< 0.05; Table 1) and plasma IGF-1 levels
(P< 0.05; Table 2) at both ages; while BA signiﬁcantly
reduced LD glycogen content at both ages (P< 0.05;
Table 2). Surprisingly, plasma glycerol levels were unaffected
(P> 0.05; Table 2) by treatment at both ages.
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Effects of BA and GH on MyHC expression in LD, SS and ST
muscles
As an indication of the effects of treatment on the ﬁbre type
composition of the LD, SS and ST muscles, MyHC expression
was determined at both the mRNA and protein levels. GH
treatment had no effects (P> 0.05) on MyHC isoform mRNA
(Table 3) or protein (Table 4) expression in any of the muscles
studied. In contrast, there were signiﬁcant effects of BA
treatment on percentage MyHC isoform mRNA expression in
all three muscles at both ages (Table 3). At D60, BA treat-
ment decreased the %MyHCI mRNA in the LD (P< 0.05), but
there were no effects in the SS and ST muscles (P> 0.05) and
there were no effects on %MyHCI mRNA expression in
any muscle at D120 (P> 0.05). BA treatment consistently
reduced %MyHCIIA mRNA expression in all three muscles at
both ages (P< 0.05). Interestingly, BA treatment increased
the %MyHCIIX/IIB mRNA expression in the two fast muscles,
LD and ST, at both ages (P< 0.05). The response observed in
Table 1 The effects of short-term (6 day) BA or GH treatment of lambs at 60 or 120 days of age on lamb carcass characteristics
D60 D120
Trait CO BA GH s.e.d. P-value CO BA GH s.e.d. P-value
n 11 10 10 11 10 10
BW (kg) 23.9 23.9 24.5 1.4 0.863 43.0 46.4 44.3 1.6 0.122
Liver (g) 475 460 567a 32 0.005 928 926 1101a 55 0.004
Muscle weights (g)
Longissimus dorsi 305 306 327 27 0.655 592 667 632 35 0.108
Supraspinatus 53.5 55.2 55.9 3.9 0.812 98.5 116.4a 98.0 6.3 0.009
Semitendinosus 63.3 67.1 65.0 4.3 0.667 112.4 131.2a 120.4 6.6 0.023
Vastus lateralis 85.4 88.0 89.3 6.3 0.815 164.5 180.3 163.8 7.5 0.058
Vastus intermedius 28.5 27.5 30.9 2.3 0.331 51.7 55.7 52.4 3.6 0.487
BA = β agonist; GH = growth hormone; CO = control.
aSigniﬁcantly different to control (Dunnett’s test; P< 0.05).
Table 2 The effects of short-term (6 day) BA or GH treatment of lambs at 60 or 120 days of age on plasma IGF-1 and glycerol concentrations and
muscle glycogen content
D60 D120
Trait CO BA GH s.e.d. P-value CO BA GH s.e.d. P-value
n 11 10 10 11 10 10
IGF-1 (ng/ml) 375 373 928a 129 <0.001 972 964 2092a 127 <0.001
Glycerol, (μg/ml) 6.3 8.2 7.3 1.1 0.191 8.2 9.4 9.5 2.4 0.826
LD Glycogen (mg/g) 25.5 19.0a 23.8 1.6 <0.001 21.6 18.3a 24.2 1.3 <0.001
BA = β agonist; GH = growth hormone; CO = control; LD = Longissimus dorsi.
aSigniﬁcantly different to control (Dunnett’s test; P< 0.05).
Table 3 The effects of short-term (6 day) BA or GH treatment of lambs at 60 or 120 days of age on MyHC isoform mRNA expression in different muscles
D60 D120
Muscle Isoform (%) CO BA GH s.e.d. P-value CO BA GH s.e.d. P-value
n 10 to 11 10 10 10 to 11 10 9 to 10
Longissimus dorsi MyHCI 7.2 3.9a 6.6 0.8 <0.001 6.8 5.0 8.1 1.9 0.277
MyHCIIA 26.9 7.0a 34.1 3.4 <0.001 21.1 5.2a 25.4 3.6 <0.001
MyHCIIX/IIB 65.9 89.1a 59.3 3.6 <0.001 72.1 89.8a 66.5 4.2 <0.001
Supraspinatus MyHCI 34.7 37.7 42.3 8.8 0.693 56.6 51.6 45.5 9.6 0.520
MyHCIIA 21.2 9.1a 27.9 3.8 <0.001 15.8 5.3a 17.2 2.1 <0.001
MyHCIIX/IIB 44.1 53.2 29.8 7.3 0.012 27.6 43.1 37.3 9.1 0.243
Semitendinosus MyHCI 13.5 8.9 11.7 2.4 0.161 11.2 14.6 13.5 2.2 0.259
MyHCIIA 20.6 4.3a 25.5 2.8 <0.001 17.1 2.7a 20.4 2.6 <0.001
MyHCIIX/IIB 66.0 86.8a 62.7 4.0 <0.001 71.7 82.7a 66.2 3.8 <0.001
BA = β agonist; GH = growth hormone; MyHC = myosin heavy chain; CO = control.
aSigniﬁcantly different to control (Dunnett’s test; P< 0.05).
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the SS muscle was similar, but either not signiﬁcant at D120
or appeared to only increase relative to the GH group at D60.
The effects of BA treatment on MyHC isoform mRNA
expression were not observed at the protein level (Table 4).
However, BA treatment did appear to reduce %MyHCIIA
protein in the LD at D60, but only relative to the GH group,
and BA tended to increase %MyHCIIX protein in the LD at
D60 and SS at D120 (Table 4).
As BA treatment signiﬁcantly increased %MyHCIIB/IIX
mRNA in the LD and ST muscles, expression of MyHCIIB
mRNA was determined by semi-quantitative RT-PCR and
compared with the expression of MyHCIIX and IIB mRNA
combined (Figure 1). MyHCIIB mRNA was induced by BA
treatment in the LD of lambs at both ages, and expression of
the MyHCIIB isoform was increased by BA in the SS and ST
muscles. However, MyHCIIB was not detected at the protein
level in any of the muscles studied (Figure 2).
Overall, the changes in MyHC isoform expression indicate
that muscles from BA-treated lambs were in transition
towards a faster, more glycolytic ﬁbre type composition, with
MyHCIIA ﬁbres switching to MyHCIIX and/or IIB ﬁbres.
Because of the observed induction of de novo mRNA
expression of the MyHCIIB isoform in the LD in response to
BA treatment, further characterisation of the metabolic
response and postulated intracellular signalling mechanisms
were conducted in that muscle.
Effects of BA and GH on metabolic enzyme activities of LD
ICDH and LDH activities were determined in the LD as an
indication of oxidative and glycolytic metabolic activities,
respectively (Table 5). ICDH activity was signiﬁcantly
decreased in BA treated lambs at both ages (P< 0.05); but
there were no effects of treatment on LDH activities
(P> 0.05, Table 5). Overall, the LD appears to be changing to
a less oxidative metabolism, which would agree with the
Table 4 The effects of short-term (6 day) BA or GH treatment of lambs at 60 or 120 days of age on MyHC isoform protein expression in different
muscles
D60 D120
Muscle Isoform (%) CO BA GH s.e.d. P-value CO BA GH s.e.d. P-value
n 11 10 10 11 10 10
Longissimus dorsi MyHCI 10.2 9.4 9.4 1.1 0.680 8.1 8.9 8.2 1.0 0.802
MyHCIIA 33.3 29.9 35.0 1.8 0.028 31.9 30.7 33.3 1.5 0.236
MyHCIIX/IIB 56.5 60.7 55.6 2.3 0.060 60.0 60.4 58.4 1.8 0.533
Supraspinatus MyHCI 42.1 45.4 42.0 8.2 0.852 48.4 34.2 47.2 8.5 0.166
MyHCIIA 20.6 19.2 22.0 2.0 0.387 20.3 18.2 17.7 1.6 0.429
MyHCIIX/IIB 37.3 35.3 36.0 6.7 0.916 31.3 47.6 35.1 7.6 0.086
Semitendinosus MyHCI 11.0 9.0 8.7 1.8 0.308 7.3 9.2 6.9 1.7 0.347
MyHCIIA 26.3 26.2 29.1 1.5 0.142 25.0 24.0 24.8 2.0 0.920
MyHCIIX/IIB 62.7 64.8 62.2 2.8 0.578 67.8 66.8 68.2 3.3 0.870
BA = β agonist; GH = growth hormone; MyHC = myosin heavy chain; CO = control.
Figure 1 Representative semi-quantitative RT-PCR for myosin heavy
chain (MyHC) IIB and IIB+ IIX mRNAs in (a) Longissimus dorsi (LD),
(b) Supraspinatus (SS) and (c) Semitendinosus (ST) muscles from D60 and
D120 lambs. The 6-day administration of β agonist (BA) induced the
expression of MyHCIIB mRNA in the LD, with no expression of this
transcript in either the control (CO) or Growth Hormone (GH) treated
lambs. BA also increased MyHCIIB expression in the SS and ST muscles.
Figure 2 Representative SDS–PAGE separation of myosin heavy chain
(MyHC) isoforms in (a) Longissimus dorsi (LD), (b) Supraspinatus (SS) and
(c) Semitendinosus (ST) muscles from D60 and D120 lambs. + ve
represents a bovine Longissimus thoracis sample containing all four adult
MyHC isoforms (kindly provided by Dr Brigitte Picard, INRA, France). The
arrows indicate the position of MyHC isoforms as determined from this
bovine + ve control sample.
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changes in MyHC isoform mRNA expression described
previously.
Effects of BA and GH on signalling molecules and regulatory
factors in LD
The enzyme activity (Table 5) or mRNA expression (Table 6)
of selected mediators thought to inﬂuence muscle contractile
and/or metabolic properties were determined in LD. Surpris-
ingly, the activities of the calcium dependent signalling
enzymes, CaN and CaMKII, were unaffected by treatment at
either age (P> 0.05 for all, Table 5). There were no sig-
niﬁcant effects of treatment on PGC-1α mRNA expression at
either age (P> 0.05, Table 6), whereas PGC-1β mRNA
expression was signiﬁcantly reduced by both BA and GH
treatment at D60 (P< 0.05, Table 6), but only by BA treat-
ment at D120 (P< 0.05, Table 6). In contrast, RIP140 mRNA
expression was signiﬁcantly increased by BA treatment at
both ages (P< 0.05, Table 6). GH treatment reduced PPARα
mRNA expression in the D120 lambs (P< 0.05, Table 6), but
there were no effects at D60 (P> 0.05, Table 6). Similarly, BA
increased PPARδ mRNA expression in the D120 lambs
(P< 0.05, Table 6), but there were no effects in the D60 lambs
(P> 0.05, Table 6). PPARγ mRNA expression was unaffected
by treatment (P>0.05 for all, Table 6) at either age. Surprisingly,
Six1 and Eya1 mRNA expression were signiﬁcantly decreased
by BA treatment in both age groups (P< 0.05, Table 6).
There were no signiﬁcant treatment effects (P> 0.05,
Table 6) on Myf-5 or MRF4 mRNA expression at either age,
nor on MyoD mRNA expression in the D60 lambs, but BA
treatment reduced MyoD mRNA expression in the D120 lambs
(P<0.05, Table 6). In contrast, BA treatment increased myo-
genin mRNA expression at both ages (P<0.05), suggesting a
possible effect on myogenic/satellite cell differentiation.
Discussion
The major ﬁndings from this sheep study relate to BA
administration which, at both ages, induced changes that are
Table 5 The effects of short-term (6 day) BA or GH treatment of lambs at 60 or 120 days of age on metabolic and signalling enzyme activities in the
Longissimus dorsi
D60 D120
Trait CO BA GH s.e.d. P-value CO BA GH s.e.d. P-value
n 10 to 11 7 to 9 10 10 to 11 9 to 10 10
ICDH activity (mOD/min per mg tissue) 49.3 33.9a 49.4 4.9 0.004 37.3 28.2a 33.1 3.4 0.041
LDH activity (mOD/min per mg tissue) 510 489 519 86 0.928 637 618 652 114 0.957
CaMKII (pmol/min per µg protein) 11.5 14.3 10.9 2.1 0.246 13.8 14.9 11.5 1.8 0.160
CaN (×10−3) arbitrary units 49.5 43.0 44.4 15.5 0.901 34.1 27.1 22.5 11.1 0.562
BA = β agonist; GH = growth hormone; CO = control; ICDH = isocitrate dehydrogenase; LDH = lactate dehydrogenase; CaMKII = calmodulin kinase II;
CaN = calcineurin.
aSigniﬁcantly different to control (Dunnett’s test; P< 0.05).
Table 6 The effects of short-term (6 day) BA or GH treatment of lambs at 60 or 120 days of age, on mRNA expression of regulators of muscle
contractile and metabolic properties in the Longissimus dorsi
D60 D120
Gene mRNA targeta CO BA GH s.e.d. P-value CO BA GH s.e.d. P-value
n 11 10 10 11 10 10
PPARα 4.46 3.82 3.94 0.31 0.096 4.53 3.74 2.91b 0.35 <0.001
PPARδ 4.30 5.75 4.08 0.86 0.124 3.82 5.14b 4.22 0.35 0.002
PPARγ 4.85 2.91 4.39 1.76 0.516 4.46 3.45 4.14 0.48 0.111
PGC1α 4.53 4.36 3.70 0.77 0.521 4.28 4.67 3.85 0.58 0.376
PGC1β 5.11 2.87b 3.85b 0.45 <0.001 4.16 2.68b 3.42 0.44 0.007
RIP140 3.59 5.58b 4.30 0.66 0.015 3.86 5.63b 3.98 0.55 0.005
Six1 4.31 2.58b 4.11 0.41 <0.001 4.66 2.24b 4.24 0.27 <0.001
Eya1 4.38 2.73b 4.29 0.53 0.006 5.35 2.93b 5.04 0.69 0.002
MyoD 2.95 2.66 2.73 0.40 0.735 3.00 2.01b 3.28 0.39 0.008
Myogenin 3.34 4.65b 3.65 047 0.023 3.15 4.54b 3.23 0.40 0.002
MRF4 3.02 4.47 3.59 1.36 0.552 4.08 4.14 5.06 0.63 0.230
Myf-5 2.71 3.69 3.22 0.40 0.059 4.33 3.71 3.71 0.57 0.436
BA = β agonist; GH = growth hormone; CO = control; PPAR = peroxisome proliferator-activated receptor; PGC = PPAR-γ coactivator; RIP = receptor-interacting
protein; MRF = myogenic regulatory factor.
aValues for gene targets expressed as arbitrary units per unit total RNA.
bSigniﬁcantly different to control (Dunnett’s test; P< 0.05).
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indicative of muscle ﬁbre type transitions towards a fast
glycolytic phenotype, with de novo expression of MyHCIIB
mRNA being observed. These changes in MyHC isoform
mRNA expression corresponded with a decrease in oxidative
metabolism, which are likely induced by the increase in
RIP140 and corresponding decrease in PGC-1β mRNA
expression.
Responsiveness to agents
Both GH and BA have previously been shown to induce
skeletal muscle hypertrophy and have the effect of reparti-
tioning nutrients from adipose tissue towards skeletal
muscle; but they are thought to do this via different
mechanisms (National Research Council, 1994). The majority
of anabolic effects exerted by GH are thought to be mediated
indirectly via the stimulation of IGF-1 production by the liver
and other tissues (Bell et al., 1998), whereas the effects of
GH on adipose tissue are thought to be direct. In contrast,
BAs are thought to act directly on tissues (particularly
muscle) by binding to β2-adrenergic receptors (β2-ARs)
expressed by those tissues (National Research Council,
1994). In the present study, very different effects of GH and
BA treatment were observed, particularly on factors indica-
tive of ﬁbre type transitions and potential regulatory factors.
Despite only a short-term (6 day) treatment, the lambs
responded to both agents at both ages, although the mag-
nitude of the responses did vary with age. At both ages,
plasma IGF-1 levels and liver weights were increased by GH,
which are commonly observed responses to GH administra-
tion (Brameld et al., 1996). As expected, BA decreased LD
glycogen content at both ages. Surprisingly, neither agent
altered plasma glycerol concentrations, which is commonly
used as an indicator of adipose tissue lipolysis. Previous
studies have shown that free fatty acid levels remain ele-
vated during chronic BA administration, but plasma glycerol
concentrations return to a basal level (O’Connor et al., 1991).
At D60, there were no effects of either treatment on
muscle weights, whereas at D120, BA treatment signiﬁcantly
increased SS and ST weights. Therefore, there was an
age differential in terms of muscle weight responses to BA
administration, with older animals responding more. The
reason for the lack of an effect on muscle weights in the
younger lambs is unclear, but may be due to lower receptor
numbers, a decreased binding afﬁnity for the agonist or a
more rapid desensitisation to the BA (National Research
Council, 1994). It has previously been suggested that fast
muscle ﬁbres are more responsive to BA administration and
that selective hypertrophy occurs in these ﬁbres (Kim et al.,
1987). However, there was a greater muscle weight response
in the slower SS compared with the LD, which has the higher
proportion of fast ﬁbres. Of interest is the fact that a sig-
niﬁcant increase in muscle weight was observed in the ST but
not the LD, which have very similar MyHC compositions.
This suggests that MyHC composition may not be a major
factor in determining muscle responses to BA administration.
Further histochemical analysis (data not included) showed
that the increased ST weights were associated with increased
muscle ﬁbre diameters (i.e. hypertrophy), with the fast ﬁbres
being mainly affected. However, we did not determine
whether similar increases in ﬁbre diameter were present in
the LD as well.
Changes in MyHC isoforms
There were no effects of GH treatment for 6 days on the
relative expression of the MyHC isoforms at either the mRNA
or protein levels. This may simply reﬂect the short (6 day)
administration period, as increases in MyHCIIX protein have
been reported in humans after a more chronic (12 week)
period of GH treatment (Lange et al., 2002). In contrast,
MyHC isoform transitions were observed at the mRNA level
in response to BA treatment. BA induced a signiﬁcant
decrease in the %MyHCI and/or IIA mRNA in all three
muscles studied, as well as an increase in the %MyHCIIX/IIB
mRNA in the LD and ST. Importantly, BA induced de novo
MyHCIIB mRNA expression in the LD (where it is not normally
expressed) and increased MyHCIIB expression in the SS and
ST. These differences were not observed at the protein level,
but this may be due to the MyHC proteins having a slower
rate of turnover compared with the corresponding mRNA, as
the half-life of the MyHC proteins is up to 30 days (Kay, 1978).
Therefore, it appears that BA is initiating changes in gene
expression that are indicative of ﬁbre type transitions, but the
6-day treatment may be insufﬁcient to see a signiﬁcant
response at the protein level. Initially it was thought that
MyHCIIB was not expressed in large mammals (Hämäläinen
and Pette., 1995); however, it is expressed at both the mRNA
and protein level in pigs (Lefaucheur et al., 2004). More
recently MyHCIIB protein expression has been observed in
muscles of the Blonde d’Aquitaine breed of bull (Picard and
Cassar-Malek, 2009), but not other breeds of cattle. As in our
previous paper (Hemmings et al., 2009), MyHCIIB was not
expressed at the protein level in any of the three sheep muscles
studied. It does, however, appear to have a low level of
expression at the mRNA level in the SS and ST muscles, which
was subsequently increased by BA treatment.
Interestingly, our data is similar to that of Vuocolo et al.
(2007), who showed that MyHCIIB is expressed at the mRNA
level in muscles from callipyge sheep. Like BA treatment, the
callipyge phenotype results in muscle hypertrophy and a
switch in ﬁbre type, with a decrease in type I ﬁbres and a
shift towards type IIX and IIB ﬁbres. When compared with
normal (wild type) sheep, the authors reported 13- and 6-fold
increases in MyHCIIB expression at birth and 12 weeks of age
in the callipyge sheep. In that study (Vuocolo et al., 2007),
four adult MyHC isoforms were detected at the mRNA level
in sheep LD skeletal muscle, with MyHCIIX being the pre-
dominant isoform and MyHCIIB being expressed at extremely
low levels (⩽1% of total adult MyHC expression). The effects
of BA treatment are therefore very similar to the callipyge
sheep phenotype. Longer term administration of BA might
therefore result in the de novo expression of MyHCIIB pro-
tein, the isoform not normally expressed at the protein level
in sheep muscles (Hemmings et al., 2009). The observed
decrease in oxidative capacity (ICDH activities) suggests that
Anabolic agents and muscle ﬁbre type transitions
291
BA treatment is driving muscle ﬁbres towards a faster, less
oxidative ﬁbre type, consistent with previous observations in
rats (Polla et al., 2001), cattle (Cassar-Malek et al., 1998) and
pigs (Gunawan et al., 2007).
It has been suggested that the switch in ﬁbre type
contributes to the muscle hypertrophy associated with BA
administration, as glycolytic ﬁbres have a larger cross-
sectional area (Lefaucheur and Gerrard, 2000). An alter-
native theory is that the switch in ﬁbre type might be
secondary to the hypertrophy that occurs as a result of BA
treatment (Gunawan et al., 2007). On the basis of the current
study, it seems unlikely that the changes in MyHC are sec-
ondary to the hypertrophy, as changes in mRNA expression
have already been observed in the LD at both ages, before
signiﬁcant changes in muscle weight. Our alternative
hypothesis is that the ﬁbre type transitions are simply a
mechanism for the muscle to adapt to changes in availability
of energy substrates, with changes in metabolism preceding
changes in contractile properties. BA treatment not only
stimulates glycogenolysis in skeletal muscles (Sensky et al.,
2006), it also increases plasma glucose concentrations
(Eisemann et al., 1988). Therefore, the muscle ﬁbres might
simply be adapting to the increased glucose availability,
which may have a particularly pronounced effect in rumi-
nants, given that they are more dependent on acetate and
other volatile fatty acids for energy metabolism. The sig-
niﬁcant effects of BA on MyHC expression in the LD muscle,
with a strong induction of MyHC IIB expression, provide a
good model for characterising the signalling events involved
in ﬁbre type switching towards a faster phenotype.
Effects of treatment on signalling molecules and regulatory
factors
CaN and CaMKII activity. CaN and CaMKII are calcium
dependent signalling molecules implicated in both muscle
hypertrophy (Dunn et al., 1999; Chin, 2005) and muscle ﬁbre
type transitions (Chin, 2005; Bassel-Duby and Olson, 2006),
as they are thought to regulate the slow oxidative phenotype
(Naya et al., 2000; Chin, 2005). Both are activated by cal-
cium, being dependent on the frequency of the intracellular
ﬂuctuations in calcium concentration (Chin et al., 1998; Chin,
2005). CaN has been shown to increase MyHCIIA expression
(Allen and Leinwand, 2010) and potentially decrease
MyHCIIX and IIB expression (Da Costa et al., 2007) in mouse
C2C12 muscle cells. Neither GH nor BA treatment affected
the activities of either of these enzymes and therefore we
conclude that the observed changes in MyHC expression and
metabolism were independent of changes in activity of the
CaN/ calmodulin kinase pathway in this study. Obviously we
cannot discount that effects of these agents on this pathway
may occur before or after 6 days.
Metabolic regulatory factors. Transcriptional co-activators of
the PGC-1 family, as well as the co-repressor RIP140, have
previously been shown to inﬂuence the metabolic capacity of
muscle ﬁbres, with PGC-1 increasing oxidative metabolism
and RIP140 decreasing it (Lin, 2009). Indeed, they appear to
have opposite effects and actually counter each other in their
transcriptional regulatory roles. In the current study, there
was no effect of BA treatment on PGC-1α mRNA expression,
but PGC-1β mRNA was signiﬁcantly decreased by BA at
both ages, coincident with the observed decrease in oxida-
tive metabolism. This might suggest that PGC-1β, rather
than PGC-1α, plays an important role in regulating the BA-
induced changes in oxidative metabolism in sheep muscle.
The lack of an effect on PGC-1α mRNA expression was
unexpected as it is thought to mediate the effects of exercise
on muscle, which involves β2-AR stimulation (Miura et al.,
2007). Indeed, administration of the β2-adrenergic agonist,
clenbuterol, has previously been shown to decrease PGC1α
mRNA and protein expression, as well as oxidative metabo-
lism, in rat muscles (Hoshino et al., 2011). However,
administration of the endogenous β-adrenergic agonist,
adrenaline, had no effect on the expression of PGC-1αmRNA
in human muscle (Viguerie et al., 2004) and the authors
suggested that the effects of adrenaline on PGC-1α expres-
sion may be species dependent. Our data would appear to
agree with this suggestion.
RIP140 mRNA expression was increased by BA adminis-
tration, which agrees with a recent study in rats (Hoshino
et al., 2011). This increase, together with the decrease in
PGC-1β mRNA, coincides with the decrease in oxidative
metabolism, suggesting that these two factors are involved
in the BA-induced metabolic response.
The PPAR nuclear receptors are targets of PGC-1 and
RIP140 co-activation/co-repression and are thought to be
major players in regulating lipid metabolism (Hock and Kralli,
2009). In the current study, BA increased PPARδ mRNA
expression, which may be involved in the increased energy
expenditure observed previously in response to short-term
BA treatment (MacRae et al., 1988). PPARα expression was
decreased in response to GH treatment, but what role/affect
this has on muscle function or metabolism is still unclear. As
the short-term administration of GH did not alter MyHC
expression or any of the metabolic measurements in the LD,
the lack of effects on the various signalling molecules is
unsurprising. However, GH did have signiﬁcant effects on
PGC-1β and PPARα mRNA expression, both of which are
associated with metabolic changes (Hock and Kralli, 2009)
and may therefore indicate that changes in muscle
metabolism might be observed if GH were administered for
longer. The altered expression of these metabolic regulatory
genes in response to BA treatment gives additional support
to the hypothesis that changes in MyHC isoform expression
(and presumably ﬁbre type transitions) are metabolically
driven. The fact that changes in oxidative metabolism (ICDH
activity) appear to precede any changes in protein levels of
the MyHC isoforms, would support this. These key metabolic
regulators may represent alternative signalling mechanisms
for BA to the well-characterised signalling through β2-ARs
and the cAMP activated second messenger pathway.
Six1 and Eya1. In recent years, a number of factors have been
identiﬁed that regulate the slow oxidative muscle phenotype,
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particularly the stimulatory effects of the PGC-1 and PPAR
pathways on oxidative metabolism and mitochondrial bio-
genesis and function. In comparison, relatively little is known
about the factors that regulate the fast glycolytic phenotype.
The transcription factor Six1 and cofactor Eya1, have been
identiﬁed as initiating a shift in expression towards a faster
muscle phenotype in mice (Grifone et al., 2004). However,
our data would appear to contradict this as both factors
were downregulated when the shift towards a faster, less
oxidative phenotype was observed in LD in response to BA
treatment. It has been reported that Six1 mRNA expression
was downregulated in human skeletal muscle in response
to lengthening contractions as early as 3 h after exercise
(Kostek et al., 2007), whereas other genes associated with
muscle hypertrophy (FHC1 and NEXN) were upregulated.
Hence, Six1 may actually be a negative regulator of muscle
hypertrophy that responds to BA treatment in sheep as well
as to exercise in humans.
MRFs. The development and differentiation of muscle is
dependent on the MRFs, MyoD, Myf-5, myogenin and MRF4.
Muscle ﬁbre number is thought to be ﬁxed at birth in most
large mammals and therefore postnatal muscle growth
relates to ﬁbre hypertrophy. This is thought to be dependent
upon the differentiation and fusion of satellite cells to
existing muscle ﬁbres in order to increase the DNA content of
ﬁbres (Brameld et al., 1998). There are also suggestions that
the MRFs may inﬂuence muscle ﬁbre type composition, as
MyoD mRNA expression is highest in fast glycolytic muscles
of rats, whereas myogenin expression is highest in slow
oxidative muscles (Hughes et al., 1993). BA administration
signiﬁcantly increased myogenin and decreased MyoD
mRNA expression. As these changes coincided with the
decrease in oxidative metabolism, the increase in MyHCIIX/
IIB mRNA and induction of MyHCIIB mRNA, this would
appear to contradict previous studies linking MyoD and
myogenin mRNA expression with ﬁbre type transitions in
rats. However, as indicated above, the MRFs have other roles
in skeletal muscle development, particularly satellite cell
proliferation and fusion with muscle ﬁbres during muscle
regeneration and hypertrophy. One possible explanation for
the described effects of BA in sheep muscle, is that BA
increases satellite cell differentiation/fusion, which would be
associated with increased myogenin and reduced MyoD
expression (Brown et al., 2012). In addition, the activities/
functions of these transcription factors may be dependent upon
their phosphorylation status rather than simply the relative
mRNA or protein expression (Puri and Sartorelli, 2000).
Conclusion
Over the 6-day time-course, BA had greater effects on muscle
growth and phenotype than GH, especially in the older
lambs. The BA-induced muscle growth was associated with
changes in phenotype indicative of transitions towards a fast
glycolytic ﬁbre type in all muscles studied. The BA response
included the induction of MyHCIIB mRNA expression, an
isoform not normally expressed in sheep LD. These changes
in MyHC expression corresponded with a decrease in oxida-
tive metabolism (ICDH activity), which was likely induced by
the combination of an increase in RIP140 and a decrease in
PGC-1β mRNA expression. However, it remains unclear what
(if any) factors are involved in driving towards the fast gly-
colytic ﬁbre type, as expression of the previously suggested
regulatory factors, Six1 and Eya1, was reduced by BA treatment.
Our interpretation of the observations in this study are that
changes in energy metabolism or substrate availability precede
the changes in contractile proteins, but identiﬁcation of the key
factors involved in driving towards the fast glycolytic ﬁbre type
remains elusive.
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